Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TA-650 (infliximab) in Behcet's disease with special lesions
NCT01532570Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Jan 2012
- Primary completion
- May 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of infliximab in Behcet's disease (BD), sponsored by Mitsubishi Tanabe Pharma. Started Jan 2012; status: completed.
02
Drugs
infliximab
03
Conditions
Behcet's disease (BD)
Beyond the preview
Go deeper on NCT01532570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01532570.